Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 592 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR New tool to tackle gaps in public’s knowledge of blood cancer... July 14, 2023 Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... December 12, 2020 Pursuing precision medicine in a flagship lung cancer trial July 15, 2020 A New Online Tool Predicts RFS and OS Probabilities in Patients... February 7, 2024 Load more HOT NEWS Sacituzumab Govitecan Improves Outcomes Over Single-Agent Chemotherapy in Patients with Pretreated... The incredible value of going public ΥΓΡΗ ΒΙΟΨΙΑ: ΤΟ ΜΕΛΛΟΝ ΣΤΗ ΔΙΑΓΝΩΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer...
